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Lack of Evidence of HHV-8 DNA in Blood Cells From Heart Transplant Recipients

To the Editor:
We looked for the presence of HHV-8 DNA in 54 buffy-coat samples from 28 KS-negative immunosuppressed heart transplant recipients and 134 control buffy-coat samples from healthy blood The human herpesvirus type 8 (HHV-8), previously named as donors. Periodical shell-vial culturing of oropharyngeal washing Kaposi's sarcoma-associated herpesvirus (KSHV), 1 has been sugshowed reactivation of cytomegalovirus (CMV), and/or herpes simgested to play a major role in the etiology and the pathogenesis of plex virus 1 (HSV-1) in 18 of the 28 (64.3%) transplant patients acquired immunodeficiency syndrome (AIDS)-associated and iatroduring immunosuppressive treatment. DNA from buffy-coat cells genic Kaposi's sarcoma (KS). In addition, evidence for HHV-8 was prepared by a ''salting out'' procedure and polymerase chain involvement in primary effusion and possibly other human B-cell reaction (PCR) suitability of the samples was assessed by amplificalymphomas has been recently provided.
2 Although a role for HHVtion of a human b-globin gene region. One microgram of each DNA 8 in the pathogenesis of the above neoplasms is presently accepted sample was tested for the presence of HHV-8 DNA sequences by by most investigators, controversial results have been obtained in nested PCR amplification. 7 HHV-8 PCR was performed on 1 to 4 molecular epidemiology studies with regard to the distribution of serial samples per transplant patient, of whom at least one was drawn the virus in the healthy population. Two recent reports have shown at the time when CMV and/or HSV-1 reactivation was demonstrated. detection of HHV-8 DNA sequences in semen from the vast majority Reconstruction experiments with titrated cloned HHV-8 templates of healthy adults 3 and in peripheral blood mononuclear cells (PBMC) showed that the nested amplification procedure used was able to from Ç10% of healthy subjects, 4 suggesting that HHV-8 is a fairly detect five copies of target DNA sequence. However, HHV-8 DNA common virus latently infecting humans. Thus, the involvement of was found neither in the blood donors nor in the transplant patients, HHV-8 in KS lesions 1 and in non-KS skin lesions from immunosupincluding those with concomitant reactivation of CMV and/or pressed transplant recipients 5 raises the possibility that the virus can HSV-1. reactivate in the presence of various immunosuppression conditions.
Our failure to detect HHV-8 DNA sequences in buffy-coat cells By contrast, other investigators have failed to identify HHV-8 DNA from the healthy blood donors and the transplant patients examined in non-KS skin lesions from immunosuppressed transplant patients 6 and in PBMC from a healthy adult population. To the Editor: to infectious complications in about one third of neutropenic patients.
8
Because 2-CdA toxicity could be partly related to the administraThe treatment options for hairy-cell leukemia (HCL) have intion schedule of the drug, in the attempt to reduce the number and creased rapidly in the last 10 to 15 years. HCL patients currently severity of complications, particularly crucial in those patients showcan benefit from several agents such as a-interferon (a-IFN), deoxying severe pancytopenia at the onset of the treatment, we investigated coformycin (DCF), and 2-chlorodeoxyadenosine (2-CdA). Despite the effectiveness and toxicity of 2-CdA administered with a different complete remission (CR) rates ranging from 5% to 10% with aregimen. In a selected group of HCL patients, showing a more IFN 1,2 to 70% to 80% with DCF 3,4 and 2-CdA, 5-7 the prognosis for a pronounced impairment of peripheral blood values (hemoglobin patient with HCL has improved dramatically with an overall survival
[Hb] level õ10 g/dL; neutrophil count õ1 1 10 g/dL; platelet count superior to 10 years with any of these treatments. Given these consid-õ100 1 10 g/dL), 2-CdA was administered at a dose of 0.15 mg/ erable results, it is extremely important to reduce in these patients kg once a week for 6 courses. any risk of toxic deaths usually related to severe infectious complicaTwenty-five HCL patients, 22 males and 3 females with a median tions more frequently observed after treatment with 2-CdA. In fact, age of 56 years (range 37 to 71), entered this protocol. Twelve of it is well known that this agent, either administered as a continuous 25 patients were enrolled at the time of diagnosis while the remaining infusion (c.i.) for 7 days or as a 2-hour infusion for 5 days, frequently induces severe neutropenia and CD4 lymphocytopenia, both leading 13 were previously treated. 
